- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03626493
A Research on Hidden Blood Loss in Laparoendoscopic Single-site Radical Hysterectomy With Pelvic Lymphadenectomy
October 27, 2020 updated by: Second Affiliated Hospital of Wenzhou Medical University
The aim of this cross-sectional study is to evaluate the hidden blood loss in patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy and identity its risk factors.
Study Overview
Status
Unknown
Detailed Description
The electronic medical data of 105 patients who undergo laparoendoscopic single-site radical hysterectomy in the following year to treat cervical cancer will be analyzed retrospectively in this study.
The amount of hidden blood loss will be calculated according to Gross's formula.
And multiple linear regression analysis will be employed to identify its risk factors.
Study Type
Observational
Enrollment (Anticipated)
105
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- TING LI
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
The planned sample size was based on data from a previous study, in which the standard deviation was 5. We assumed an one-tailed α error of 0.05 and a sampling error of 1.0.
we propose to enroll 105 participants and allow for a dropout rate of 10% for an effective sample size of 100.
Description
Inclusion Criteria:
- Volunteer to participate in the study with informed consent;
- Females aged 20-80 who are confirmed with cervical cancer and are treated with laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy.
Exclusion Criteria:
- Pregnancy, lactation, postmenopause, or planned pregnancy within two years;
- Suspected or identified as other tumors of genital tract;
- History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune diseases, or digestive system diseases (malabsorption, crohn disease and dysentery);
- Other diseases or heavy injuries that will interfere with the results;
- Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
|---|
|
LSRH
patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the volume of hidden blood loss (mL)
Time Frame: 10 months after the operation
|
the specific volume of hidden blood loss in patients after the operation applying Gross's formula
|
10 months after the operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the risk factors of hidden blood loss
Time Frame: 10 months after the operation
|
Performing multiple linear regression analysis with SPSS 17.0, we plan to identify the risk factors which can increase the volume of hidden blood loss from possible factors like hypertension, diabetes, etc.
|
10 months after the operation
|
|
the volume of total blood loss (mL)
Time Frame: 10 months after surgery
|
the volume of blood loss happened to patients through the whole perioperative period accoring to the method of Nadler
|
10 months after surgery
|
|
the volume of visible blood loss (mL)
Time Frame: 10 months after surgery
|
the volume of visible blood loss including the blood in the suction bottle and in weighed compresses during the operation and the drainage volume as the post-operative blood loss
|
10 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2022
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
August 6, 2018
First Submitted That Met QC Criteria
August 8, 2018
First Posted (Actual)
August 13, 2018
Study Record Updates
Last Update Posted (Actual)
October 29, 2020
Last Update Submitted That Met QC Criteria
October 27, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAHoWMU-CR2018-07-131
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.